慢性乙型肝炎抗病毒治疗与血清HBsAg和HBcrAg水平的变化

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (2892 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：探讨核苷（酸）类抗病毒治疗与慢性乙型肝炎（CHB）患者血清HBsAg和HBcrAg水平的变化。方法：108例CHB患者入选本研究，其中HBeAg阳性患者分别进入抗病毒组46例和非抗病毒组20例，HBeAg阴性患者进入抗病毒组31例和非抗病毒组11例。血清HBsAg和HBcrAg分别采用化学发光微粒免疫法和化学发光酶免疫法检测。结果：无论HBeAg阳性或阴性患者，抗病毒组与非抗病毒组随访时间差异均无统计学意义（P＞0.05）；抗病毒组随访起点与终点血清HBsAg和HBcrAg水平差异均有统计学意义（均P＜0.05），非抗病毒组随访起点与终点血清HBsAg和HBcrAg水平差异均无统计学意义（均P＞0.05）；抗病毒组与非抗病毒组从随访起点到终点血清HBsAg下降幅度和下降比例差异均无统计学意义（均P＞0.05），从随访起点到终点血清HBcrAg下降幅度和下降比例差异均有统计学意义（P＜0.05）。结论：CHB患者的抗病毒治疗能导致显著的血清HBsAg和HBcrAg下降，但只能获得显著的血清HBcrAg下降幅度和下降比例。

	服务
	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李健
	陆伟
	张占卿
	王雁冰
	翁齐铖
	张智勇
	丁荣蓉
	周新兰

关键词 ：慢性乙型肝炎, 核苷（酸）类, 抗病毒治疗, 乙型肝炎表面抗原, 乙型肝炎核心相关抗原

Abstract：Objective: To investigate the changes of serum hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels in patients with chronic hepatitis B treated with nucleos(t)ides antiviral therapy. Methods: One hundred and eight patients of chronic hepatitis B patients were enrolled in this study, 46 patients and 20 patients of HBeAg-positive patients respectively were divided into the antiviral group and the non-antiviral group, 31 patients and 11 patients of HBeAg-negative patients respectively were into the antiviral group and the non-antiviral group. Serum HBsAg and HBcrAg levels were respectively detected by chemiluminescence microparticle immunoassay and chemiluminescence enzyme immunoassay. Results: In both HBeAg-positive and HBeAg-negative patients, the differences of the follow-up time between antiviral and non-antiviral group were no statistically significant (P>0.05); the differences of serum HBsAg and HBcrAg levels between the follow-up start and the follow-up end were statistically significant in antiviral group (P<0.05), and which of serum HBsAg and HBcrAg levels between the follow-up start and the follow-up end were not statistically significant in non-antiviral group (P>0.05); the differences of serum HBsAg levels decline extent and proportion from follow-up start to the follow-up end between antiviral and non-antiviral group were not statistically significant (P>0.05), and which of HBcrAg decline extent and proportion from follow-up start to the follow-up end between antiviral and non-antiviral group were statistically significant. Conclusion: The antiviral therapy of CHB patients can lead to the significant decrease of serum HBsAg and HBcrAg levels, but can only get the significant decline extent and proportion of serum HBcrAg.

Key words： chronic hepatitis B nucleos(t)ides antiviral therapy hepatitis B surface antigen hepatitis B core-related antigen

收稿日期: 2016-01-12

基金资助:上海市卫计委重点科研项目（20134032）；国家“十二五”传染病防治重大科技专项（2013ZX10002005）。

通讯作者: 张占卿，主任医师，硕士生导师，Email：doctorzzqsphc@163.com。

作者简介: 李健（1991-），男，浙江杭州人，硕士生。

链接本文:

https://xb.wmu.edu.cn/CN/ 或 https://xb.wmu.edu.cn/CN/Y2016/V46/I11/807

[1] RUSSO F P, RODRÍGUEZ-CASTRO K, SCRIBANO L,et al. Role of antiviral therapy in the natural history of hepatitis B virus-related chronic liver disease[J]. World J Hepatol, 2015, 18, 7(8): 1097-1104.
[2] CHEN C H, CHIU Y C, LU S N, et al. Serum hepatitis B surface antigen levels predict treatment response to nucleos (t) ide analogues [J]. World J Gastroenterol, 2014, 20 (24): 7686-7695.
[3] TANAKA E, MATSUMOTO A, YOSHIZAWA K, et al. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy[J]. Intervirology, 2008, 51(Suppl 1): 3-6.
[4] MOMMEJA-MARIN H, MONDOU E, BLUM M R, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature[J]. Hepatology, 2003, 37(6): 1309-1319.
[5] XU Y, ZHANG Y G, WANG X, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis[J]. World J Gastroenterol, 2015, 21(25): 7869-7876.
[6] CROAGH C M, LUBEL J S. Natural history of chronic hepatitis B: Phases in a complex relationship[J]. World J Gastroenterol, 2014, 20(30): 10395-10404.
[7] CHAN H L, WONG V W, WONG G L, et al. A longitudinal study on the natural history of serum hepatitis b surface antigen changes in chronic hepatitis B[J]. Hepatology, 2010, 52(4): 1232-1241.
[8] JAROSZEWICZ J, SERRANO B C, WURSTHORN K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: A European perspective[J]. J Hepatol, 2010, 52(4): 514-522.
[9] NGUYEN T, THOMPSON A J, BOWDEN S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: A perspective on Asia[J]. J Hepatol, 2010, 52(4): 508-513.
[10] KIM Y J, CHO H C, CHOI M S, et al. The change of quantitative HBsAg level in the natural course of chronic hapatitia B[J]. Liver Int, 2011, 31(6): 817-823.
[11] BRUNETTO M R, OLIVERI F, COLOMBATTO P, et al. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers[J]. Gastroenterology, 2010, 139(2): 483-490.
[12] CHUNG K H, KIM W, KIM B G, et al. Hepatitis B surface antigen quantification across different phases of chronic hepatitis b virus infection using an immunoradiometric assay[J].Gut Liver, 2015, 9(5): 657-664.
[13] SETO W K, WONG D K, FUNG J, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B[J]. Clin Microbiol Infect, 2014, 20(11): 1173-1180.
[14] MAASOUMY B, WIEGAND S B, JAROSZEWICZ J, et al. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D[J]. Clin Microbiol Infect, 2015, 21(6): 606.e1-10.
[15] 张占卿, 陆伟, 王雁冰, 等. 血清 HBsAg和HBV DNA预测慢性乙型肝炎肝组织病理状态的评价[J]. 胃肠病学和肝病学杂志, 2014 , 23(5): 554-558.
[16] 曾达武, 董菁, 陈丽红, 等. 免疫清除期慢性乙型肝炎患者血清HBsAg水平与肝组织炎症分级及纤维化分期的关系[J]. 中华肝脏病杂志, 2012, 20(10): 746-750.
[17] MARTINOT-PEIGNOUX M, CARVALHO-FILHO R, LAPALUS M, et al. Hepatitis B surface antigen serum level is associated with fibrosis severity in treatment-naїve e antigen-positive patients[J]. J Hepatol, 2013, 58(6): 1089-1095.
[18] JIA W, QI X, JI Y Y, et al. Low serum hepatitis B surface antigen level predicts compensated cirrhosis caused by chronic hepatitis B in HBeAg positive patients in East China[J]. Hepat Mon, 2015, 15(8): e29183.
[19] CROAGH C M, BELL S J, SLAVIN J, et al. Increasing hepatitis B viral load is associated with risk of signi¢cant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B[J]. Liver Int, 2010, 30(8): 1115-1122.
[20] ALAM S, AHMAD N, MUSTAFA G, et al. Evaluation of normal or minimally elevated alanine transaminase, age and DNA level in predicting liver histological changes in chronic hepatitis B[J]. Liver Int, 2011, 31(6): 824-830.
[21] MCMAHON B J, BULKOW L, SIMONS B, et al. Relationship between level of HBV DNA and liver disease-a population-based study of hepatitits B e antigen-negative persons with hepatitis B[J]. Clin Gastroenterol Hepatol, 2014, 12(4): 701-706.
[22] SANAI F M, HELMY A, BZEIZI K I, et al. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B[J]. J Viral Hepat, 2011, 18(7): e217-e225.
[23] 张占卿, 陆伟, 翁齐铖, 等. 血清乙型肝炎核心相关抗原预测慢性乙型肝炎肝组织病理状态的评价[J]. 肝脏, 2015, 20(8): 576-582.
[24] 张占卿, 陆伟, 翁齐铖, 等. 血清病毒学标记物预测慢性乙型肝炎肝组织病理状态的评价[J]. 同济大学学报(医学版), 2015, 36(4): 57-63.
[25] WU J F, CHANG M H. Natural history of chronic hepatitis B virus infection from infancy to adult life-the mechanism of inflammation triggering and long-term impacts[J]. J Biomed Sci, 2015, 22: 92.
[26] 张占卿, 陆伟, 沈芳, 等. 乙型肝炎病毒复制及其抗原表达水平与慢性乙型肝炎肝组织病理状态的相关性[J]. 胃肠病学和肝病学杂志, 2015, 24(7): 829-836.
[27] 张玉果, 王泰龄. 慢性乙型肝炎肝组织内HBsAg、HBcAg的表达及临床研究进展[J]. 胃肠病学和肝病学杂志, 2010, 19(2): 189-192.
[28] HUANG Y H, HUNG H H, CHAN C C, et al. Core antigen expression is associated with hepatic necroinflammation in e antigen-negative chronic hepatitis B patients with low DNA loads [J]. Clin Vaccine Immunol, 2010, 17(6): 1048-1053.